| Editor's Note: FierceLifeSci will not publish next week, November 29, for the U.S. Thanksgiving holiday, but will return to your inboxes Dec. 6. Multibillion-dollar settlements used to be rare in the pharma industry—but that could be changing. In the past weeks alone, we’ve seen Teva’s $23 billion deal to end thousands of opioid lawsuits, as well as a $4 billion opioid-related pact for Johnson & Johnson, though both have yet to be approved. If they are, they would buck the trends seen in recent years, with state and federal settlements staying relatively flat compared to the boom seen in 2012 and 2013, where 117 deals totaled $9.8 billion. Our top ten since 2018 and the most-read stories of the week are below.. | |
|
Featured Story | | | Saturday, November 16, 2019 Another candidate for Novartis' future blockbuster club is here. Now armed with an early FDA approval for Adakveo, the Swiss drugmaker will launch the first targeted therapy to prevent painful vaso-occlusive crises in sickle cell disease patients. |
|
|---|
|
Top Stories Of The Week Friday, November 15, 2019 Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process. Tuesday, November 19, 2019 A number of high-dollar settlements could be on the way as drugmakers look to bail on federal opioid suits. But the past two years have been thick with other deals to wrap up government investigations and lawsuits, from Medicaid fraud to False Claims Act actions. Monday, November 18, 2019 The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12. CooperVision’s MiSight lens is a soft, single-use and disposable contact, made to be discarded at the end of each day. Sunday, November 17, 2019 PHILADELPHIA—Amgen's Repatha may already be far ahead in the PCSK9 field, but new competition is on its way. A new analysis in high-risk heart attack patients could give it some more ammo for that fight. Tuesday, November 19, 2019 The Medicines Company, fresh from its turn at the American Heart Association this weekend, has seen its shares jump on growing rumors that Swiss major Novartis may be interested in buying it out. Tuesday, November 19, 2019 While new multiple sclerosis drugs from Novartis, Merck KGaA and Biogen have hit the market this year, all bearing blockbuster hopes, one group of doctors wasn't all that interested in them. Instead, a repurposed therapy not yet approved for MS attracted “unanimous excitement,” an analyst said. Tuesday, November 19, 2019 Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans. Friday, November 15, 2019 GlaxoSmithKline has been laboring to boost supplies of next-gen shingles vaccine Shingrix, thanks to a speedy launch that bested all expectations. While it's planning a slight increase next year, the real "step change" will come in 2024 with a brand-new facility, CEO Emma Walmsley recently said. Wednesday, November 20, 2019 Scientists from Gladstone Institutes and Boston University used machine learning and CRISPR-Cas9 gene-editing tools to control the patterns stem cells form in lab dishes, which they suggest is an important step to create functional organs for research or therapeutic purposes. Wednesday, November 20, 2019 Eli Lilly faced critics of rising insulin prices this year by introducing a generic version of its popular Humalog priced at half the cost. Now the drugmaker is investing $400 million in its Indianapolis production site so it can make more diabetes treatments and prepare for pipeline products. Enrollment Showcase Resources Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 